Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OncoGenex Technologies and Isis Pharmaceuticals have commenced a phase II clinical trial of the developmental cancer drug, OGX-011, in combination with conventional cancer treatments in patients with advanced non-small cell lung cancer.
Subscribe to our email newsletter
This trial is designed to specifically assess the safety and efficacy of OGX-011 in tandem with gemcitabine and cisplatin, a commonly used chemotherapeutic regimen, in patients with non-small cell lung cancer.
OGX-011 is a targeted therapeutic that sensitizes tumors that are resistant to conventional cancer treatments, such as chemotherapy, hormone ablation therapy and radiation therapy. The drug targets the protein clusterin, which is highly expressed in many cancers including prostrate, lung and breast cancer. Clusterin is a cell survival protein that is increased in cancer cells in response to standard anti-cancer treatments, preventing cancer cell death and undermining the effectiveness of standard anti-tumor therapies.
“We are pleased to achieve another product development milestone for OGX-011,” stated Scott Cormack, president and chief executive of OncoGenex. “The initiation of this second phase II trial demonstrates our commitment to build a robust data package for OGX-011 in a variety of solid tumor indications.”